BIOMAT Database Logo BIOMAT Database Logo

Cilostazol is Effective to Prevent Stroke-Associated Pneumonia in Patients Receiving Tube Feeding. 2018

Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Department of Neurology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Stroke-associated pneumonia (SAP) is a frequent complication in acute ischemic stroke (IS) patients, especially those receiving tube feeding (TF). In this retrospective study, we investigated whether or not cilostazol, a pluripotent phosphodiesterase III-specific inhibitor with anti-platelet and vasculogenic effects, can prevent SAP in these patients and reduce their duration of stay in intensive care unit/hospitalization. We recruited 158 IS patients receiving TF. Patients' characteristics (including age, gender, past history), National Institute of Health Stroke Scale and serum albumin level on admission, concomitant medications associated with SAP prevention (including cilostazol), and stroke characteristics (bilateral subcortical white matter lesion, brainstem involvement, large infarction, and asymptomatic hemorrhagic infarction) were compared between the SAP(-) and SAP(+) groups. Cilostazol was more frequently used in the SAP(-) group (20.8% vs. 6.1%, p < 0.05). Duration of intensive care unit was longer in patients with SAP (9 ± 8 vs. 6 ± 6 days, p < 0.05). However, the length of stay in an intensive care unit and duration of hospitalization were not reduced due to the prevention of SAP by cilostazol treatment. Cilostazol administration was associated with reduced SAP incidence in acute IS patients receiving TF.

UI MeSH Term Description Entries
D008297 Male Males
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D004750 Enteral Nutrition Nutritional support given via the alimentary canal or any route connected to the gastrointestinal system (i.e., the enteral route). This includes oral feeding, sip feeding, and tube feeding using nasogastric, gastrostomy, and jejunostomy tubes. Enteral Feeding,Force Feeding,Nutrition, Enteral,Tube Feeding,Gastric Feeding Tubes,Feeding Tube, Gastric,Feeding Tubes, Gastric,Feeding, Enteral,Feeding, Force,Feeding, Tube,Feedings, Force,Force Feedings,Gastric Feeding Tube,Tube, Gastric Feeding,Tubes, Gastric Feeding
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077407 Cilostazol A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke. 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone,OPC 13013,OPC-13013,Pletal
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Use of tube feeding to prevent aspiration pneumonia.
November 1996, Lancet (London, England),
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding.
August 2018, Geriatrics & gerontology international,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
January 2006, Cerebrovascular diseases (Basel, Switzerland),
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Is overnight tube feeding associated with hypoxia in stroke?
November 2006, Age and ageing,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Is tube feeding associated with altered arterial oxygen saturation in stroke patients?
September 2004, Age and ageing,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Is looped nasogastric tube feeding more effective than conventional nasogastric tube feeding for dysphagia in acute stroke?
August 2007, Trials,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
The feeding tube bridle: one inexpensive, safe, and effective method to prevent inadvertent feeding tube dislodgement.
February 2011, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Effects of functional training of dysphagia to prevent pneumonia for patients on tube feeding.
June 2004, Gerodontology,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Correction to: Quick and effective improvement of leucine enriched dietary supplement on malnutrition in acute stroke patients receiving enteral tube feeding.
December 2020, BMC emergency medicine,
Shizuka Netsu, and Atsushi Mizuma, and Masaki Sakamoto, and Sachiko Yutani, and Eiichiro Nagata, and Shunya Takizawa
Quick and effective improvement of leucine enriched dietary supplement on malnutrition in acute stroke patients receiving enteral tube feeding.
July 2020, BMC emergency medicine,
Copied contents to your clipboard!